Enlivex Therapeutics Files 6-K Update
Ticker: ENLV · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1596812
Sentiment: neutral
Topics: financial-update, foreign-private-issuer, sec-filing
Related Tickers: ENLV
TL;DR
Enlivex (ENLV) dropped a 6-K with Q2 financials. Check it out.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting its financial statements for the period ending June 30, 2025. The company, formerly known as Bioblast Pharma Ltd., is a foreign private issuer based in Israel. This filing provides an update on its financial status.
Why It Matters
This filing provides investors with unaudited financial information for Enlivex Therapeutics, crucial for understanding the company's performance and financial health as of mid-2025.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain unaudited financial information and updates, which can be less comprehensive than audited reports, introducing a degree of uncertainty.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Bioblast Pharma Ltd. (company) — Former company name
- August 29, 2025 (date) — Filing date
- June 30, 2025 (date) — Reporting period end date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report the unaudited financial statements of Enlivex Therapeutics Ltd. for the period ending June 30, 2025.
When was Enlivex Therapeutics Ltd. formerly known as?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd., with a name change date of September 19, 2016.
Where is Enlivex Therapeutics Ltd. located?
Enlivex Therapeutics Ltd. is located at 14 Einstein Street, Nes Ziona, Israel 7403618, and its business address is in Tel Aviv, Israel.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F or 40-F?
Enlivex Therapeutics Ltd. files its annual reports under cover of Form 20-F.
What is the SEC file number for Enlivex Therapeutics Ltd.?
The SEC file number for Enlivex Therapeutics Ltd. is 001-36578.
Filing Stats: 359 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2025-08-29 16:16:03
Filing Documents
- ea0254617-6k_enlivex.htm (6-K) — 16KB
- ea025461701ex99-1_enlivex.htm (EX-99.1) — 517KB
- ea025461701ex99-2_enlivex.htm (EX-99.2) — 80KB
- 0001213900-25-082585.txt ( ) — 4184KB
- enlv-20250630.xsd (EX-101.SCH) — 47KB
- enlv-20250630_cal.xml (EX-101.CAL) — 35KB
- enlv-20250630_def.xml (EX-101.DEF) — 185KB
- enlv-20250630_lab.xml (EX-101.LAB) — 378KB
- enlv-20250630_pre.xml (EX-101.PRE) — 210KB
- ea0254617-6k_enlivex_htm.xml (XML) — 601KB
Financial Statements
Financial Statements The unaudited condensed consolidated financial of and for the three and six month periods ended June 30, 2025 and 2024, and the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex's registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799 , File No. 333-232413 , File No. 333-232009 , File No. 333-252926 and File No. 333-286956 ), filed with the Securities and Exchange Commission. Exhibit No. 99.1 Unaudited condensed consolidated financial statements for Enlivex as of June 30, 2025 and December 31, 2024 and for the three and six month periods ended June 30, 2025 and 2024. 99.2 Operating and Financial Review and Prospects as of and for the three and six month periods ended June 30, 2025 and 2024. 101.INS Inline XBRL Instance Document 101.SCH Inline Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Defeinition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: August 29, 2025 2